Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

INTELGENX TECHNOLOGIES CORP. (IGX)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 0,54 M
EBIT 2018 -9,41 M
Net income 2018 -7,06 M
Debt 2018 -
Yield 2018 -
Sales 2019 6,96 M
EBIT 2019 -6,77 M
Net income 2019 -3,36 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 87,3x
Capi. / Sales2019 6,76x
Capitalization 47,0 M
More Financials
Company
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.Its products include rizaport, tadalafil, loxapine, and montelukast.It also offers a comprehensive portfolio of pharmaceutical services, such as... 
Sector
Pharmaceuticals
Calendar
08/08Earnings Release
More about the company
Latest news on INTELGENX TECHNOLOGIES COR
05/18INTELGENX TECHNOLOGIES : Announces Settlement of Suboxone Patent Litigation
AQ
05/17INTELGENX TECHNOLOGIES : Reports First Quarter 2018 Financial Results
AQ
05/15INTELGENX TECHNOLOGIES : Performance and Restricted Share Unit Plan Approved by ..
AQ
05/14IntelGenx Announces Settlement of Suboxone® Patent Litigation
GL
05/14INTELGENX TECHNOLOGIES : Closes Private Placement Financing
AQ
05/11INTELGENX : 1Q Earnings Snapshot
AQ
05/10INTELGENX TECHNOLOGIES CORP. : Management's Discussion and Analysis of Financial..
AQ
05/10IntelGenx Reports First Quarter 2018 Financial Results
GL
05/10INTELGENX TECHNOLOGIES CORP. : Entry into a Material Definitive Agreement, Unreg..
AQ
05/10INTELGENX TECHNOLOGIES CORP. : Submission of Matters to a Vote of Security Holde..
AQ
More news
Sector news : Generic Pharmaceuticals
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/18LONDON MARKETS: U.K. Stocks Fall From Record As AstraZeneca, Mining Stocks De..
DJ
05/18Correction to Buybacks Article on May 10
DJ
05/18NOVARTIS : Greek Parliament to Vote on Prosecutions in Novartis Bribery Case
DJ
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 115%
EPS Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin CFO, Principal Accounting Officer & Executive VP
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
J. Bernard Boudreau Vice Chairman